Page 600 - TNFlipTest

H60 Hematology References Toronto Notes 2019 References
American Society of Hematology Choosing Wisely Recommendations. Available from: http://www.choosingwisely.org/societies/american-society-of-hematology/ Armitage JO. Treatment of Non-Hodgkin’s lymphoma. NEJM 1993;328:1023-1030.
Bataille R, Harousseua J. Multiple myeloma. NEJM 1997;336:1657-1664.
Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. NEJM 2004;351:268-277.
Bazemore AW, Smucker DR. Lymphadenopathy and malignancy. Am Fam Phys 2002;66;2103-2110.
Bottomly SS. Causes of the hereditary and acquired sideroblastic anemias. Rose BD (editor). Waltham: UpToDate. 2006.
Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference Statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008;148:932-938.
Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane DB Syst Rev 2014;8:CD008980.
Callum JL. Idiopathic thrombocytopenia purpura. Available from: http://sunnybrook.ca/uploads/Idiopathic_Thrombocytopenia_Purpura.pdf
Callum JL, Pinkerton PH. Bloody easy, 3rd ed. Toronto: Sunnybrook and Women’s College Health Sciences Centre, 2011. Blood transfusions, blood alternatives and transfusion reactions.
Canadian Blood Services Surveillance Report 2014. Available from: http://www.cps.ca/documents/position/transfusion-and-risk-of-infection-Canada
Canadian Pediatric Society. Transfusion and risk of infection in Canada: update 2012. Paediatr Child Health 17(10):e102-e111
Carson JL, Terrin ML, Noveck H, et al. Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery. NEJM 2011;365:2453-2462.
Castellone DD. Saunders Manual of Clinical Laboratory Science. Philadelphia: WB Saunders, 1998. Evaluation of bleeding disorders.
Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent thrombotic events. JAMA 2005;293:2353-2361.
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. NEJM 2002;346:995-1008.
Coates TD, Baehner RL. Causes of neutrophilia. Rose BD (editor). Waltham: UpToDate. 2006.
Cohen K, Scadden DT. Non-Hodgkin’s lymphoma: pathogenesis, clinical presentation, and treatment. Cancer Treat Res 2001;104:201-203.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009;361:1139-1151.
Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. NEJM 1998;338:409-415.
Driscoll MC. Sickle cell disease. Ped Rev 2007;28:259-286.
Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. NEJM 2006;355:2408-2417.
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. NEJM 2010; 362:2499-2510.
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement; a randomized, double-blind, non-inferiority trial. Lancet 2007;379:949-956.
Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Ann Rev Med 2011;62:41-57.
Fleming RE, Ponka P. Iron overload in human disease. NEJM 2012;366:348-359.
Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126L:3385-4005.
George JN. Treatment and prognosis of idiopathic thrombocytopenic purpura. Rose BD (editor). Waltham: UpToDate. 2005.
Goldman J. ABC of clinical haematology: chronic myeloid leukaemia. BMJ 1997;314:657.
Habermann TM, Steensma DP. Lymphadenopathy. Mayo Clinic Proc 2000;75:723-732.
Haddad H, Tyan P, Radwan A, et al. B-Thalassemia Intermedia: A Bird’s-Eye View. Turk J Haematol 2014;31:5-16.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. NEJM 1998;339:1506-1514.
Health Canada. Effects of lead on human health. Available from: http://www.hc-sc.gc.ca/ewh-semt/contaminants/lead-plomb/asked_questions-questions_posees-eng.php#exposure
Heaney ML, Golde DW. Myelodysplasia. NEJM 1999;340:1649-1660.
Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
Kopko PM, Holland PV. Mechanisms of severe transfusion reactions. Transfus Clin Biol 2001;8:278-281.
Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation monograms together with low-molecular-weight heparin for out patient treatment of acute venous thromboembolism. Ann Intern Med 2003;138:714-719.
Kyle RA, Rajkumar SV. Chemotherapy in multiple myeloma. Rose BD (editor). Waltham: UpToDate. 2006.
Kyle RA, Rajkumar SV. Clinical manifestations and diagnosis of Waldenstrom’s macroglobulinemia. Rose BD (editor). Waltham: UpToDate. 2006.
Landaw SA. Approach to the adult patient with thrombocytopenia. Rose BD (editor). Waltham: UpToDate. 2006.
Leonardi-Bee J, Bath PM, Bousser MG, et al. Review: dipyridamole given with or without Aspirin® reduces recurrent stroke. ACP Journal Club 2005;143:10.
Liesner RJ, Machin SJ. ABC of clinical haematology: platelet disorders. BMJ 1997;314:809.
Liesner RJ, Goldstone AH. ABC of clinical haematology: the acute leukaemias. BMJ 1997;314:733.
Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4-T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765.
Lowenberg B. Downing JR, Burnett A. Acute myeloid leukemia. NEJM 1999;341:1051-1062.
MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MInT Group. Lancet Oncol 2011;12:1013-1022.
Mackie IJ, Bull HA. Normal haemostasis and its regulation. Blood Rev 1989;3:237-250.
Markovic M, Majkic-Singh N, Subota V. Usefulness of soluble transferrin receptor and ferritin in iron deficiency and chronic disease. Scan J Clin Lab Invest 2005;65:571-576.
Mead GM. ABC of clinical haematology: malignant lymphomas and chronic lymphocytic leukaemia. BMJ 1997;314:1103.
Messinezy M, Pearson TC. ABC of clinical haematology: polycythaemia, primary (essential) thrombocythaemia and myelofibrosis. BMJ 1997;314:587.
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
Pangalis GA, Vassilakopoulos TP, Boussiotis VA, et al. Clinical approach to lymphadenopathy. Semin Oncol 1993;20:570-582.
Park JH, Rivière I, Gonen M et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449.
Pillot G, Chantler M, Magiera H, et al. (editors). The Washington Manual Hematology and Oncology Subspecialty Consult. Philadelphia: Lipincott Williams & Wilkins, 2004.
Pui C, Evans WE. Acute lymphoblastic leukemia. NEJM 1998;339:605-615.
Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane DB Syst Rev 2015;6: CD010956.
Rozman C, Montserrat E. Chronic lymphocytic leukemia. NEJM 1995;333:1052-1057.
Sabatine MS (editor). Pocket medicine, 2nd ed. The Massachusetts General Hospital Handbook of Internal Medicine. Philadelphia: Lippincott Williams & Wilkins, 2004. Hematology-oncology.
Seiter K. Acute lymphoblastic leukemia. E-medicine 2015. Available from: http://emedicine.medscape.com/article/207631-overview.
Sawyers C. Chronic myeloid leukemia. NEJM 1999;340:1330-1340.
Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members’ practice patterns. Blood 2002;99:1144-1149. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. NEJM 2009;361:2342-2352.
Tefferi A. Approach to the patient with thrombocytosis. Rose BD (editor). Waltham: UpToDate. 2006.
The Merck Manual. Section 11, Chapter 133: Platelet disorders.
Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001;161:2433-2439.
U.S. Consumer Product Safety Commission. Ban of lead-containing paint and certain consumer products bearing lead-containing paint. Available from: http://www.cpsc.gov/BUSINFO/regsumleadpaint.pdf.
Valentine KA, Hull RD. Clinical use of warfarin. Rose BD (editor). Waltham: UpToDate. 2006.
Valentine KA, Hull RD. Clinical use of heparin and low molecular weight heparin. Rose BD (editor). Waltham: UpToDate. 2006.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
Verstovsek S, Mesa RA, Gotlib J, et al. A Double-blind, placebo-controlled trial of ruxolitinib for Myelofibrosis. NEJM 2012;366:799-807.
Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. NEJM 2003;349:1227-1235.
Wilson SE, Watson HG, Crowther MA. Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 2004;170:821-824.